Skip to main content

Advertisement

SpringerLink
Log in

High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan

  • Pharmacovigilance
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Treatment of systemic lupus erythematosus (SLE) often continues with moderate-to-low doses of glucocorticoids for the long term. Bisphosphonates aid in the prevention and management of glucocorticoid-induced osteoporosis (GIOP). However, long-term use of bisphosphonates increases the relative risk of atypical femoral fracture (AFF) and the incidence is typically 16 or 113 per 100,000 person-years in patients treated with bisphosphonates for 5 or 10 years, respectively. Here, we explored bisphosphonate prescription rate and prevalence of AFF in patients with SLE. In total, 270 patients with SLE were enrolled. The Japanese Society for Bone and Mineral Research Guideline 2014 for GIOP management and treatment was used. We also explored AFF history through medical records. Most (n = 251) patients were recommended to treat by the GIOP guideline (scores ≥ 3); bisphosphonates, denosumab, teriparatide, or active vitamin D was prescribed for 85.7%. Bisphosphonates were currently used by 66.1% of the patients, and 65% had used them for ≥ 5 years. Of all patients, 76.7% had a history of bisphosphonate use, 5 of 270 (1.9%) had histories of AFF. Four of five patients with AFF had taken bisphosphonates for ≥ 3.5 years, in addition to moderate doses (≥ 10 mg/day) of glucocorticoids. For the SLE patients with a history of bisphosphonate use, the incidence of AFF was calculated to be 278 per 100,000 person-years. Our single-center study found that bisphosphonates were commonly used long term by Japanese patients with SLE. As AFF is not rare, AFF should be cared in patients with SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H et al (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337–350

    Article  PubMed  Google Scholar 

  2. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J et al (2017) 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521–1537

    Article  PubMed  Google Scholar 

  3. Briot K, Cortet B, Roux C, Fardet L, Abitbol V et al (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine 81:493–501

    Article  PubMed  Google Scholar 

  4. Compston J, Bowring C, Cooper A, Cooper C, Davies C et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392–396

    Article  CAS  Google Scholar 

  5. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Trijau S, de Lamotte G, Pradel V, Natali F, Allaria-Lapierre V et al (2016) Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database. RMD Open 2:e000249

    Article  PubMed  PubMed Central  Google Scholar 

  7. Feldstein AC, Elmer PJ, Nichols GA, Herson M (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16:2168–2174

    Article  CAS  PubMed  Google Scholar 

  8. Duyvendak M, Naunton M, Atthobari J, van den Berg PB, Brouwers JR (2007) Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001–2005. Osteoporos Int 18:1429–1433

    Article  CAS  PubMed  Google Scholar 

  9. Klop C, de Vries F, Vinks T, Kooij MJ, van Staa TP et al (2014) Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial. Osteoporos Int 25:385–392

    Article  CAS  PubMed  Google Scholar 

  10. Overman RA, Toliver JC, Yeh JY, Gourlay ML, Deal CL (2014) United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 66:1644–1652

    Article  Google Scholar 

  11. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:1910

    Article  CAS  PubMed  Google Scholar 

  12. Saita Y, Ishijima M, Mogami A, Kubota M, Baba T et al (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 33:311–318

    Article  CAS  PubMed  Google Scholar 

  13. Sato H, Kondo N, Wada Y, Nakatsue T, Iguchi S et al (2016) The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates. Osteoporos Int 27:1217–1225

    Article  CAS  PubMed  Google Scholar 

  14. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  15. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23

    Article  PubMed  Google Scholar 

  16. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301

    Article  CAS  PubMed  Google Scholar 

  17. Kondo N, Fukuhara T, Watanabe Y, Miyasaka D, Yamamoto N et al (2017) Bone formation parameters of the biopsied Ilium differ between subtrochanteric and diaphyseal atypical femoral fractures in bisphosphonate-treated patients. Tohoku J Exp Med 243:247–254

    Article  CAS  PubMed  Google Scholar 

  18. Kondo N, Yoda T, Fujisawa J, Arai K, Sakuma M et al (2015) Bilateral atypical femoral subtrochanteric fractures in a premenopausal patient receiving prolonged bisphosphonate therapy: evidence of severely suppressed bone turnover. Clin Cases Miner Bone Metab 12:273–277

    PubMed  PubMed Central  Google Scholar 

  19. Girgis CM, Sher D, Seibel MJ (2010) Atypical femoral fractures and bisphosphonate use. N Engl J Med 362:1848–1849

    Article  CAS  PubMed  Google Scholar 

  20. Sato H, Kondo N, Nakatsue T, Wada Y, Fujisawa J et al (2017) High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates. Osteoporos Int 28:2367–2376

    Article  CAS  PubMed  Google Scholar 

  21. Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC et al (2017) Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 32:3–10

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health Administration Center, Niigata University, 2-8050 Ikarashi, Nishiku, Niigata City, 950-2181, Japan

    Hiroe Sato, Takeshi Kuroda & Yoshiki Suzuki

  2. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuoku, Niigata City, 951-8510, Japan

    Hiroe Sato, Ayako Wakamatsu, Daisuke Kobayashi, Takeshi Nakatsue, Yoko Wada & Ichiei Narita

  3. Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuoku, Niigata City, 951-8510, Japan

    Naoki Kondo & Naoto Endo

  4. Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, 2-746 Asahimachi-Dori, Chuoku, Niigata City, 951-8518, Japan

    Masaaki Nakano

Authors
  1. Hiroe Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoki Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayako Wakamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeshi Nakatsue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoko Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takeshi Kuroda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshiki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masaaki Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoto Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ichiei Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HS, NK, AW, DK, TN, and YW collected and analyzed the data. HS wrote the initial draft of the manuscript. NK, TK, YS, MN, EN, and IN assisted in the interpretation of the data and preparation of the manuscript. All of the authors have critically reviewed the manuscript and approved the final version of the manuscript.

Corresponding author

Correspondence to Hiroe Sato.

Ethics declarations

Conflicts of interest

All authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sato, H., Kondo, N., Wakamatsu, A. et al. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Rheumatol Int 39, 1803–1810 (2019). https://doi.org/10.1007/s00296-019-04407-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-019-04407-4

Keywords

Search

Navigation